June 10, 2025

FDA OCE Announces Project Interface Outreach Initiative

The Oncology Center of Excellence (OCE) at the FDA has launched Project Interface to advance engagement and outreach to patients with cancer, advocacy organizations, and oncology experts. Its mission ...

The ASCO Post

June 04, 2025

EMR-Integrated Messaging Drastically Increases Cancer-Related Fertility Preservation Referrals

The integration of a

The ASCO Post

September 26, 2023

Catalyzing Change: Young Moroccan Oncologists Spearhead the Fight Against Sarcoma

Discover the latest insights into sarcoma and rare adult solid cancers from the recent ESMO Sarcoma and Rare Cancers Congress, underlining the significance of multidisciplinary approaches and research efforts. Voices from young oncologists shed light on the pressing need for qualified resources. #ESMO2023

The ASCO Post

June 19, 2023

Aromatase Inhibitors May Limit Effectiveness of Weight Loss Medications in Breast Cancer Survivors

Aromatase inhibitors may interfere with the efficacy of weight loss medications in breast cancer survivors, according to a new study presented by Fansa et al at the 2023 Endocrine Society Annual Meeti...

The ASCO Post

October 04, 2023

Using Recent Diagnostic Scans May Cut Time to Treatment for Patients Needing Urgent Palliative Radiotherapy

Using previously taken diagnostic CT scans in place of CT simulation scans to plan simple palliative radiation treatments may substantially reduce the time spent waiting for urgent treatment, improvin...

The ASCO Post

June 05, 2024

Impact of High Blood Insulin Levels on Triple-Negative Breast Cancer Survival in Black Women

High blood insulin levels may contribute to worse outcomes in Black women with triple-negative breast cancer, according to new findings presented at the Endocrine Society’s Annual Meeting & Exposi...

The ASCO Post

June 10, 2024

FDA’s Oncology Center of Excellence Launches Project 5 in 5, a Crowdsourcing Initiative

The Oncology Center of Excellence initiates 'Project 5 in 5,' a crowdsourcing initiative to identify and answer clinically relevant questions using FDA-approved oncology therapies through pragmatic clinical trials over the next 5 years.

The ASCO Post

September 09, 2024

What Is the Better Target for Bispecific Antibodies in Multiple Myeloma: BCMA or GPRC5D?

For relapsed or refractory multiple myeloma, there are three available bispecific antibodies—two that target B-cell maturation antigen (BCMA) and one that targets G protein–coupled receptor class C gr...

The ASCO Post

May 25, 2023

Elena Garralda, MD, MSc, Discusses Findings From the KRYSTAL-1 Trial

Elena Garralda, MD, MSc, Director of Early Drug Development at Vall d’Hebron University Hospital and Director of the Phase I Unit at NEXT Oncology, Barcelona, was invited to discuss the KRYSTAL-1 find...

The ASCO Post